# Beraprost-314d Added-on to Tyvaso® (BEAT)

Study · id `cardio:ct-nct01908699` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01908699](<https://clinicaltrials.gov/study/NCT01908699>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01908699

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

## Technical summary

Registry record NCT01908699. Randomized; triple masking; primary purpose treatment. Start 2013-05-31 (actual); primary completion 2019-02-19 (actual). Results posted on 2020-02-28.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 273 participants (enrolled count; ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Started: 2013-05-31 (actual) (ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Primary completion: 2019-02-19 (actual) (ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Completion: 2019-02-19 (actual) (ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Results first posted: 2020-02-28 (ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Countries: United States; Israel (ClinicalTrials.gov record NCT01908699, source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01908699-2020-08-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Beraprost-314d Added-on to Tyvaso® (BEAT)
- Acronym: BEAT
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Beraprost Sodium 314d Modified Release Tablets
- Intervention (Drug): Placebo
- Lead sponsor: Lung Biotechnology PBC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 08b0e3f41eb33bef31fa159f971efdf6033cd9df1ec1f89ac09a968822c74f55
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
